Published on April 22nd, 2026 by Bob Ciura
Real Estate Investment Trusts, or REITs, give investors a hands-off way to participate in real estate’s economic upside.
They have grown in popularity over time as income investors seek alternative strategies to generate portfolio income.
One side effect of the growing popularity of REITs is the emergence of specialized REITs, which focus on only one subsector of the real estate industry.
For example, Chiron Real Estate (XRN) is a major healthcare REIT.
It also pays monthly dividends to shareholders.
You can download our full Excel spreadsheet of all 119 monthly dividend stocks (along with metrics that matter, like dividend yield and payout ratio) by clicking on the link below:
The stock’s high dividend yield and monthly payments make it a solid choice for income investors.
This article will discuss the investment prospects of Chiron Real Estate in detail.
Business Overview
Chiron Real Estate is a healthcare real estate company focused on owning net-lease healthcare facilities, off-campus outpatient medical buildings, and other specialized care properties leased to physician groups and regional or national health systems.
Chiron operated for years as Global Medical REIT under the ticker GMRE, but in 2025 it completed a broader repositioning and corporate rebrand to Chiron Real Estate to reflect a wider strategic focus beyond its legacy GMRE identity.
As of its latest filings, the portfolio comprised 189 properties totaling 5.1 million square feet and was 96% leased.
The asset mix was weighted toward outpatient medical properties (72%), with additional exposure to inpatient rehabilitation facilities (16%) and other healthcare real estate (12%).
On February 25th, 2026, Chiron Real Estate released Q4 and full-year results. For the year, rental revenue increased to $147.7 million from $138.4 million in 2024, while total revenue rose to $148.2 million from $138.8 million.
Adjusted Core FFO rose to $65.8 million, or $4.53 per share and unit, from $63.4 million, or $4.44 per share and unit, in 2024, while year-end leased occupancy was 96.0%.
During the year, the company completed its rebrand to Chiron, amended and extended its credit facility, issued $51.3 million of Series B preferred stock, and sold two facilities for $11.3 million as part of its portfolio repositioning efforts.
For 2026, we expect FFO per share of $4.00.
Growth Prospects
From 2017 through 2018, AFFO rose sharply as GMRE added properties and began to include rent from acquisitions completed in prior periods.
As rental revenue kept rising in 2019, AFFO per share still slipped a bit because GMRE was expanding quickly and taking on higher fees, depreciation, amortization, and interest costs from acquisitions and the capital used to fund them.
That started to reverse in 2020, then picked up in 2021–2022 as the company scaled, internalized management, kept buying medical properties, and generated more rent from a larger asset base.
By 2021, GMRE had invested about $196 million in medical real estate, helping lift AFFO per share, and 2022 marked the high point of that run.
From 2023 on, the story shifted to balance sheet pressure and portfolio cleanup. In 2023, GMRE used sale proceeds to cut leverage, which made strategic sense but held back near-term AFFO growth.
In 2024, AFFO per share slipped again as higher borrowing costs, seven property sales, CEO transition costs, and a property impairment weighed on results.
In 2025, under the Chiron Real Estate name, Core FFO improved modestly to $4.53 per share, driven by same-property cash NOI growth, recent acquisitions, and portfolio repositioning.
Moving forward, we forecast 3% growth to AFFO/share and the dividend, driven by lease escalators, stable occupancy, and selective capital recycling, supported by a balance sheet with no debt maturities until 2028.
Dividend & Valuation Analysis
While Chiron boasts a 96%-leased healthcare portfolio and no debt maturities until 2028, these metrics mask a legacy of value destruction rooted in flawed capital allocation.
The strategy under the former GMRE banner prioritized aggressive scale over asset quality, forcing the company into a cycle of “portfolio cleanup.”
This overextension led to $3.2 million in impairments in 2024 and a 2025 net loss despite rising rental revenue as the cost of asset recycling, CEO turnover, and rebranding ate into shareholder equity.
Ultimately, Chiron’s history proves that high occupancy is no substitute for a competitive moat.
Shares of XRN are trading at 9.2 times AFFO at the moment, which is slightly above our target of 9.0. Multiple contraction could deduct 0.8% from annual returns over the next five years.
Along with our expectation for 3% annual AFFO-per-share growth and the 8.5% dividend yield, we project total annual returns of 9.6% through 2031.
Final Thoughts
Chiron is a high-yield monthly dividend healthcare REIT with some defensive appeal, but the upside depends on steady execution and moving past the legacy GMRE issues that hurt investor confidence.
We see annualized returns of 9.6% through 2031, to be mainly driven by the dividend and projected growth. Chiron earns a sell rating due to the lack of dividend growth, nonetheless.
Additional Reading
Don’t miss the resources below for more monthly dividend stock investing research.
- 20 Highest Yielding Monthly Dividend Stocks
- 10 Cheapest Monthly Dividend Stocks
- 10 Safest Monthly Dividend Stocks
- 3 Top ‘Hold Forever’ Monthly Dividend Stocks
And see the resources below for more compelling investment ideas for dividend growth stocks and/or high-yield investment securities.
- Dividend Kings: 50+ years of rising dividends
- Dividend Champions: 25+ years of rising dividends
- Dividend Aristocrats: 25+ years of rising dividends and in the S&P 500
- Blue Chip Stock: Kings, Aristocrats, and Achievers
- MLPs: List of MLPs and more
- REITs: List of REITs and more
- BDCs: List of BDCs and more